US20050113367A1 - Pharmaceutical composition - Google Patents
Pharmaceutical composition Download PDFInfo
- Publication number
- US20050113367A1 US20050113367A1 US11/020,624 US2062404A US2005113367A1 US 20050113367 A1 US20050113367 A1 US 20050113367A1 US 2062404 A US2062404 A US 2062404A US 2005113367 A1 US2005113367 A1 US 2005113367A1
- Authority
- US
- United States
- Prior art keywords
- compound
- diuretic
- angiotensin
- receptor antagonist
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VTRAEEWXHOVJFV-UHFFFAOYSA-N CCCC1=NC(C(C)(C)O)=C(C(=O)O)N1CC1=CC=C(C2=C(C3=NN=NN3)C=CC=C2)C=C1 Chemical compound CCCC1=NC(C(C)(C)O)=C(C(=O)O)N1CC1=CC=C(C2=C(C3=NN=NN3)C=CC=C2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 6
- MLCGWPUVZKTVLO-UHFFFAOYSA-N O=C1C2=CC=CN=C2OC2=C1C=C(C1=NN=NN1)C=C2Cl.[NaH] Chemical compound O=C1C2=CC=CN=C2OC2=C1C=C(C1=NN=NN1)C=C2Cl.[NaH] MLCGWPUVZKTVLO-UHFFFAOYSA-N 0.000 description 2
- RPPYOGSPEZFAIE-JJBDSINSSA-N C/C(O)=N/C1=NN=C(S(N)(=O)=O)S1.CC(=O)/N=C1/SC(S(N)(=O)=O)=NN1C.CC1=CC(Cl)=C(SOON)C=C1S(N)(=O)=O.CCOC1=CC2=C(C=C1)N=C(S(N)(=O)=O)S2.CN(CC1(C)CCCO1)S(=O)(=O)C1=CC(SOON)=C(Cl)C=C1.NOOSC1=C(Cl)C(Cl)=CC(S(N)(=O)=O)=C1.NOOSC1=C(Cl)C=CC(C2(O)NC(=O)C3=C2C=CC=C3)=C1.NOOSC1=C(Cl)C=CC(S(N)(=O)=O)=C1 Chemical compound C/C(O)=N/C1=NN=C(S(N)(=O)=O)S1.CC(=O)/N=C1/SC(S(N)(=O)=O)=NN1C.CC1=CC(Cl)=C(SOON)C=C1S(N)(=O)=O.CCOC1=CC2=C(C=C1)N=C(S(N)(=O)=O)S2.CN(CC1(C)CCCO1)S(=O)(=O)C1=CC(SOON)=C(Cl)C=C1.NOOSC1=C(Cl)C(Cl)=CC(S(N)(=O)=O)=C1.NOOSC1=C(Cl)C=CC(C2(O)NC(=O)C3=C2C=CC=C3)=C1.NOOSC1=C(Cl)C=CC(S(N)(=O)=O)=C1 RPPYOGSPEZFAIE-JJBDSINSSA-N 0.000 description 1
- HYNJCNCDSCVYDC-UHFFFAOYSA-N C=C(CC)C(=O)C1=CC=C(OCC(=O)O)C(Cl)=C1Cl.CC1(C2=CC=CC=C2)CC2=C(C1=O)C(Cl)=C(Cl)C(OCC(=O)O)=C2.CCOCC1COC2=CC3=C(C=C2O1)NC=C(C(=O)OCC)C3=O.NC1=NC2=C(N=C(C3=CC=CC=C3)C(N)=N2)C(N)=N1.NOOSC1=CC2=C(C=C1C(F)(F)F)NC(CC1=CC=CC=C1)NS2(=O)=O.NOOSC1=CC2=C(C=C1C(F)(F)F)NCNS2(=O)=O.O=C(O)COC1=CC=C(C(=O)C2=CC=CS2)C(Cl)=C1Cl Chemical compound C=C(CC)C(=O)C1=CC=C(OCC(=O)O)C(Cl)=C1Cl.CC1(C2=CC=CC=C2)CC2=C(C1=O)C(Cl)=C(Cl)C(OCC(=O)O)=C2.CCOCC1COC2=CC3=C(C=C2O1)NC=C(C(=O)OCC)C3=O.NC1=NC2=C(N=C(C3=CC=CC=C3)C(N)=N2)C(N)=N1.NOOSC1=CC2=C(C=C1C(F)(F)F)NC(CC1=CC=CC=C1)NS2(=O)=O.NOOSC1=CC2=C(C=C1C(F)(F)F)NCNS2(=O)=O.O=C(O)COC1=CC=C(C(=O)C2=CC=CS2)C(Cl)=C1Cl HYNJCNCDSCVYDC-UHFFFAOYSA-N 0.000 description 1
- VOGOLJLAZNWPBY-UHFFFAOYSA-M CC(=O)SC1CC2=CC(=O)CCC2(C)C2CCC3(C)C(CCC34CCC(=O)O4)C12.CC(C)(C)C1=CC(I)=C(O)C(CN)=C1.CC12CCC(=O)C=C1C=CC1C2CCC2(C)C1CCC2(O)CCC(=O)O[K].CC1=CC=CC(NC2=C(S(=O)(=O)NC(=O)NC(C)C)C=NC=C2)=C1.Cl.N=C(N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1 Chemical compound CC(=O)SC1CC2=CC(=O)CCC2(C)C2CCC3(C)C(CCC34CCC(=O)O4)C12.CC(C)(C)C1=CC(I)=C(O)C(CN)=C1.CC12CCC(=O)C=C1C=CC1C2CCC2(C)C1CCC2(O)CCC(=O)O[K].CC1=CC=CC(NC2=C(S(=O)(=O)NC(=O)NC(C)C)C=NC=C2)=C1.Cl.N=C(N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1 VOGOLJLAZNWPBY-UHFFFAOYSA-M 0.000 description 1
- MNNAOLAJGAEFGC-UHFFFAOYSA-N CC1=CC=CC(C)=C1NC(=O)C1=CC(SOON)=C(Cl)C=C1O.CC1=CC=CC=C1N1C(=O)C2=C(C=C(Cl)C(SOON)=C2)NC1C.CCCCNC1=C(OC2=CC=CC=C2)C(SOON)=CC(C(=O)O)=C1.NOOSC1=CC(C(=O)O)=CC(N2CCCC2)=C1OC1=CC=CC=C1.NOOSC1=CC(C(=O)O)=CC(OCC2=CSC=C2)=C1C(=O)C1=CC=CC=C1.NOOSC1=CC2=C(C=C1Cl)NCNS2(=O)=O Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(SOON)=C(Cl)C=C1O.CC1=CC=CC=C1N1C(=O)C2=C(C=C(Cl)C(SOON)=C2)NC1C.CCCCNC1=C(OC2=CC=CC=C2)C(SOON)=CC(C(=O)O)=C1.NOOSC1=CC(C(=O)O)=CC(N2CCCC2)=C1OC1=CC=CC=C1.NOOSC1=CC(C(=O)O)=CC(OCC2=CSC=C2)=C1C(=O)C1=CC=CC=C1.NOOSC1=CC2=C(C=C1Cl)NCNS2(=O)=O MNNAOLAJGAEFGC-UHFFFAOYSA-N 0.000 description 1
- QKZUOHZNHLDWAK-UHFFFAOYSA-N CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC=C(Cl)C(SOON)=C1.CC1CCCC(C)N1NC(=O)C1=CC=C(Cl)C(SOON)=C1.CCC1NC(=O)C2=C(C=C(Cl)C(SOON)=C2)N1.NOOSC1=CC(C(=O)NN2CC3C4CCC(C4)C3C2)=CC=C1Cl.NOOSC1=CC(C(=O)O)=C(NCC2=CC=CO2)C=C1Cl.NOOSC1=CC2=C(C=C1Cl)CN(C1CCCCC1)C2=O Chemical compound CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC=C(Cl)C(SOON)=C1.CC1CCCC(C)N1NC(=O)C1=CC=C(Cl)C(SOON)=C1.CCC1NC(=O)C2=C(C=C(Cl)C(SOON)=C2)N1.NOOSC1=CC(C(=O)NN2CC3C4CCC(C4)C3C2)=CC=C1Cl.NOOSC1=CC(C(=O)O)=C(NCC2=CC=CO2)C=C1Cl.NOOSC1=CC2=C(C=C1Cl)CN(C1CCCCC1)C2=O QKZUOHZNHLDWAK-UHFFFAOYSA-N 0.000 description 1
- SEWGTJPAYFVGAJ-UHFFFAOYSA-N CCC1NC2=C(C=C(SOON)C(Cl)=C2)S(=O)(=O)N1.CN1C(CCl)NC2=C(C=C(SOON)C(Cl)=C2)S1(=O)=O.CN1C(CSCC(F)(F)F)NC2=C(C=C(SOON)C(Cl)=C2)S1(=O)=O.NOOSC1=CC2=C(C=C1Cl)NC(C(Cl)Cl)NS2(=O)=O.NOOSC1=CC2=C(C=C1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O.NOOSC1=CC2=C(C=C1Cl)NC(CC1=CC=CC=C1)NS2(=O)=O.NOOSC1=CC2=C(C=C1Cl)NC(CC1CCCC1)NS2(=O)=O Chemical compound CCC1NC2=C(C=C(SOON)C(Cl)=C2)S(=O)(=O)N1.CN1C(CCl)NC2=C(C=C(SOON)C(Cl)=C2)S1(=O)=O.CN1C(CSCC(F)(F)F)NC2=C(C=C(SOON)C(Cl)=C2)S1(=O)=O.NOOSC1=CC2=C(C=C1Cl)NC(C(Cl)Cl)NS2(=O)=O.NOOSC1=CC2=C(C=C1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O.NOOSC1=CC2=C(C=C1Cl)NC(CC1=CC=CC=C1)NS2(=O)=O.NOOSC1=CC2=C(C=C1Cl)NC(CC1CCCC1)NS2(=O)=O SEWGTJPAYFVGAJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a pharmaceutical composition containing a specific angiotensin II receptor antagonist and one or more diuretics as the active ingredients (particularly a pharmaceutical composition for preventing or treating hypertension), the use of a specific angiotensin II receptor antagonist and one or more diuretics for manufacturing the pharmaceutical composition (particularly a pharmaceutical composition for preventing or treating hypertension), and a method for preventing or treating (particularly treating) diseases (particularly hypertension) by the administration of a pharmaceutical composition to warm-blooded animals (particularly humans) comprising effective doses of a specific angiotensin II receptor antagonist and one or more diuretics.
- a pharmaceutical composition containing a specific angiotensin II receptor antagonist such as CS-866 ((5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazol-5-carboxylate) (U.S. Pat. No. 5,616,599), and a diuretic remain unknown.
- CS-866 ((5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazol-5-carboxylate) (U.S. Pat. No. 5,616,599), and a diuretic remain unknown.
- a pharmaceutical composition containing a specific angiotensin II receptor antagonist, such as CS-866, and one or more diuretics exerts excellent anti-hypertensive effects and hence may be useful as a preventative and/or therapeutic agent for hypertension.
- the present invention provides a pharmaceutical composition containing a specific angiotensin II receptor antagonist and one or more diuretics as the active ingredients (particularly pharmaceutical compositions for preventing or treating hypertension), the use of a specific angiotensin II receptor antagonist and one or more diuretics for manufacturing the pharmaceutical compositions (particularly pharmaceutical compositions for preventing or treating hypertension), a method for preventing or treating (particularly treating) diseases (particularly hypertension) by the administration of a specific angiotensin II receptor antagonist and one or more diuretics to warm-blooded animals (particularly humans) at effective doses, and a pharmaceutical composition for administering simultaneously or sequentially a specific angiotensin II receptor antagonist and one or more diuretics for preventing or treating hypertension.
- the active ingredients of the pharmaceutical composition of this invention include an angiotensin II receptor antagonist selected from the group consisting of a compound having the following formula (I), pharmacologically acceptable salts thereof, pharmacologically acceptable esters thereof and pharmacologically acceptable salts of said esters; and one or more diuretics.
- an angiotensin II receptor antagonist selected from the group consisting of a compound having the following formula (I), pharmacologically acceptable salts thereof, pharmacologically acceptable esters thereof and pharmacologically acceptable salts of said esters; and one or more diuretics.
- the compound of formula (I), a salt thereof and the like are known compounds, for example, described in the specification of Japanese Patent Application Kokai No. Hei 5-78328 etc. and the chemical name of the compound of formula (I) is 4(1-hydroxy-1-methylethyl)-2-propyl-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazol-5-carboxylic acid.
- the “pharmacologically acceptable salt” of the compound of formula (I), which is an active ingredient of this invention includes an alkali metal salt such as sodium salt, potassium salt or lithium salt; an alkaline earth metal salt such as calcium salt or magnesium salt; a metal salt such as aluminum salt, iron salt, zinc salt, copper salt, nickel salt or cobalt salt; or an amine salt such as ammonium salt, t-octylamine salt, dibenzylamine salt, morpholine salt, glucosamine salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine salt, N-benzylphenethylamine salt, piperazine salt, tetramethylammonium salt or tris(hydroxymethyl)
- the “pharmacologically acceptable ester” of the compound of formula (I), which is an active ingredient of this invention, is a compound esterified at the carboxyl moiety of the compound of formula (I).
- a group forming said ester is a group which can be cleaved by a biological process such as hydrolysis in vivo.
- Such groups include, for example, a (C 1 -C 4 )alkoxy-(C 1 -C 4 )alkyl group such as methoxymethyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, 1-(isopropoxy)ethyl, 2-methoxyethyl, 2-ethoxyethyl, 1,1-dimethyl-1-methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl or t-butoxymethyl; a (C 1 -C 4 )alkoxylated (C 1 -C 4 )alkoxy-(C 1 -C 4 )alkyl group such as 2-methoxyethoxymethyl; a (C 6 -C 10 )aryloxy-(C 1 -C 4 )alkyl group such as phenoxymethyl; a halogenated (C 1 -C 4 )alkoxy-(C 1 -C 4 )alkyl group such
- Preferred ester groups are a pivaloyloxymethyl group, phthalidyl group or (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group and the more preferred ester group is a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group.
- the “pharmacologically acceptable salt of the pharmacologically acceptable ester” of the compound of formula (I), which is an active ingredient of this invention includes a pharmacologically acceptable salt of the “pharmacologically acceptable ester” described above, for example, a hydrohalogenic acid salt such as hydrofluoride, hydrochloride, hydrobromide or hydroiodide; nitrate; perchlorate; sulfate; phosphate; a C 1 -C 4 alkanesulfonic acid salt, which may be optionally substituted with a halogen atom(s) such as methanesulfonate, trifiuoromethanesulfonate or ethanesulfonate; a C 6 -C 10 arylsulfonic acid salt, which may be optionally substituted with a C 1 -C 4 alkyl group(s), such as benrenesulfonate or p-toluenesulfonate; a C 1
- the angiotensin II receptor antagonist which is an active ingredient of this invention, is preferably the compound of formula (I) or a pharmacologically acceptable ester thereof, more preferably a pharmacologically acceptable ester of the compound of formula (I), and still more preferably the pivaloyloxymethyl, phthalidyl or (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of compound of formula (I).
- the most preferred compound is (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazol-5-carboxylate (CS-866).
- the compound of formula (I), which is an active ingredient of this invention, may absorb water or an organic solvent to form a hydrate or a solvate and the present invention encompasses such hydrates and solvates.
- the diuretics which are another active ingredient of this invention, are known compounds and, for example, include sulfonamide compounds such as acetazolamide, methazolamide, ethoxzolamide, clofenamide, dichlorphenamide, disulfamide, mefruside, chlorthalidone, quinethazone, furosemide, clopamide, tripamide, indapamide, chlorexolone, metolazone, xipamide, bumetanide, piretanide and X-54; thiazide compounds such as hydrochlorothiazide, methylclothiazide, benzylhydrochlorothiazide, trichloromethiazide, cyclopenthiazide, polythiazide, ethiazide, cyclothiazide, bendroflumethiazide, and hydroflumethiazide; phenoxyacetic acid compounds such as ethacrynic acid, t
- hydrochlorothiazide 6-chloro-3,4-dihydro-2H-1,2,4,-benzothiadiazin-7-sulfonamide 1,1-dioxide.
- the hydrochlorothiazide of this invention includes pharmacologically acceptable salts thereof, for example, a hydrohalogenic acid salt such as hydrofluoride, hydrochloride, hydrobromide or hydroiodide; nitrate; perchlorate; sulfate; phosphate; a C 1 -C 4 alkanesulfonic acid salt, which may be optionally substituted with a halogen atom(s) such as methanesulfonate, trifiuoromethanesulfonate or ethanesulfonate; a C 6 -C 10 arylsulfonic acid salt, which may be optionally substituted with a C 1 -C 4 alkyl group(s), such as benzenesulfonate or p-
- the present invention encompasses individual optical isomers and mixtures thereof.
- the present invention also encompasses hydrates of the compound described hereinbefore.
- the diuretic of this invention is selected from one or more compounds described hereinbefore and preferably one diuretic agent is selected, which is used in combination with an angiotensin II receptor antagonist such as CS-866.
- Preferred pharmaceutical compositions of this invention are:
- the pharmaceutical compositions are useful as remedies, i.e., preferably preventative or therapeutic agents for hypertension, heart diseases (angina pectoris, cardiac failure, cardiac hypertrophy), vascular disorders (arteriosclerosis, post-PTCA restenosis, peripheral vascular disorders), renal diseases (diabetic nephropathy, glomerular nephritis, nephrosclerosis); more preferably preventative and/or therapeutic agents (particularly therapeutic agents) for hypertension or heart diseases; and most preferably preventative or therapeutic agents (particularly therapeutic agents) for hypertension].
- the remedies described above are preferably applied to warm-blooded animals, especially to humans.
- the specific angiotensin II receptor antagonist such as CS-866 and diuretics exert better therapeutic efficacy by combined administration rather than when used separately.
- these agents exert excellent efficacy when administered to the same warm-blooded animal at different times.
- the 2 groups of compounds employed in the present invention are absorbed in warm-blooded animals, they switch on the signals at their respective receptors to cause their pharmacological actions.
- the switches located at their receptors have already been turned on and so the preventative or therapeutic effects on hypertension caused by the first drug are seen.
- the effects of the compound that is administered later are superimposed on those of the former drug.
- these 2 agents are additive and excellent effects can be observed. Since it is clinically convenient if these 2 agents are administered at the same time, the specific angiotensin II receptor antagonist, such as CS-866, and the diuretics can be administered at the same time as a single pharmaceutical composition. In the case that these agents cannot adequately be mixed physically from formulation techniques, each compound may be separately administered at the same time. Furthermore, as described above, since these 2 groups of agents do not necessarily have to be administered at the same time to get excellent therapeutic efficacy, the compounds may be administered at appropriate intervals. The maximum acceptable time interval to administer these 2 groups of compounds to obtain excellent treatment or preventative efficacy can be confirmed clinically or preclinically.
- the administration route of specific angiotensin II receptor antagonists, such as CS-866, and diuretics is generally oral.
- these 2 groups of compounds can be prepared as separate single formulations of each or as a single formulation by physically mixing these 2 groups of compounds.
- Administration formulations are, for instance, powder, granules, tablets, capsules, etc.
- the free compounds or pharmacologically acceptable salts or esters thereof are mixed with constituents, diluents, etc., and prepared according to conventional preparation techniques as described below.
- preparations as described above are manufactured by conventionally known methods using additive agents, i.e., carriers such as diluents (for instance, organic diluents including sugar derivatives such as lactose, sucrose, glucose, mannitol, sorbitol; starch derivatives such as cornstarch, potatostarch, ⁇ -starch, and dextrin; cellulose derivatives such as crystalline cellulose; gum arabic; dextran; pullulan; and inorganic diluents including silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, calcium silicate, magnesium aluminometasilicate; phosphate derivatives such as calcium hydrogenphosphate; carbonates such as calcium carbonate; and sulfate derivatives such as calcium sulfate), lubricants (for instance, metallic salts of stearic acid such as stearic acid, calcium stearate, magnesium stearate; talc; waxes such as bees,
- the dose and rate of administration of the specific angiotensin II receptor antagonist, such as CS-866, and diuretics depend upon various factors such as the drugs' activities, symptoms, age, and body weight of the patients. However, generally speaking, the adult dosage (mg dose/time) of the specific angiotensin II receptor antagonist and diuretics is 0.5 to 1,000 mg (preferably 1 to 100 mg) and about 0.05 to 1,500 mg (preferably 5 to 300 mg), respectively. Compounds are administered once or several times per day, depending upon the symptoms of the patients.
- Dosing ratios of the drugs in the 2 categories may also be varied. However, generally speaking, the rates of the specific angiotensin II receptor antagonist, such as CS-866, and diuretics are 1:200 to 200:1 as their weight ratios.
- the specific angiotensin II receptor antagonist such as CS-866, and diuretics are simultaneously administered, or separately or sequentially administered at the doses described above.
- SHRs Twenty-eight male spontaneously hypertensive rats aged 20 weeks (SHRs, SPF grade, purchased from Hoshino Laboratory Animals) were used. A transmitter of a telemeter (TA11PA-C40, DATA SCIENCES Inc.) was implanted in each SHR for recording blood pressure. After recovery from the surgical operations, blood pressure was monitored in the rats from the age of 24 weeks. The rats were orally given 0.5% carboxymethylceflulose solution (CMC, 2 ml/kg) for 7 successive days (once daily) by gavage. They were divided into 4 groups (7 SHRs per group) so as to give equally averaged blood pressure levels in the groups based on the blood pressure recorded on the 5th and 6th days after the CMC solution was initiated.
- CMC carboxymethylceflulose solution
- the rats were orally treated with 0.5% CMC solution (2 ml/kg, control group) or test substance suspended in 0.5% CMC solution (2 ml/kg) for 14 successive days (once daily). Blood pressure was monitored 1 day prior to the drug administration and on the 7th and 14th days after the drug was initiated.
- the group composition, test substances, doses and blood pressure are summarized in Tables 1 and 2.
- test substances were hydrochlorothiazide (HCTZ), CS-866, and HCTZ and CS-866.
- HCTZ was prepared so as to be 10 mg/2 ml of final concentration with 0.5% CMC solution.
- CS-866 was suspended in 0.5% CMC solution so as to be at a final concentration of 1 mg/2 ml.
- CS-866 and HCTZ solution was prepared so as to be at a final concentration of [10 mg (HCTZ)+1 mg (CS-866)]/2 ml with 0.5% CMC solution.
- the powders described above are mixed well, and tableted with a tableting machine to prepare a tablet containing 350 mg.
- the tablets can be sugar coated if desired.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
A pharmaceutical composition which comprises (i) an angiotensin II receptor antagonist having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable salt of such ester, and (ii) a diuretic which is at least one thiazide compound:
The pharmaceutical composition has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for treating hypertension or heart disease.
Description
- This application is a Continuation application of application Ser. No. 10/442,874 filed May 20, 2003, which is a Continuation application of International application No. PCT/JP01/10095, filed Nov. 19, 2001, the entire contents of which are hereby incorporated by reference herein.
- 1. Field of the Invention
- The present invention relates to a pharmaceutical composition containing a specific angiotensin II receptor antagonist and one or more diuretics as the active ingredients (particularly a pharmaceutical composition for preventing or treating hypertension), the use of a specific angiotensin II receptor antagonist and one or more diuretics for manufacturing the pharmaceutical composition (particularly a pharmaceutical composition for preventing or treating hypertension), and a method for preventing or treating (particularly treating) diseases (particularly hypertension) by the administration of a pharmaceutical composition to warm-blooded animals (particularly humans) comprising effective doses of a specific angiotensin II receptor antagonist and one or more diuretics.
- 2. Background Information
- It is known that co-administration of an angiotensin II receptor antagonist and a diuretic is an effective therapy for the prevention or treatment of hypertension (particularly treatment). These pharmaceutical compositions are described, for example, in WO89/6233, Japanese Patent Application Kokai No. Hei 3-27362 and the like.
- However, the effects of a pharmaceutical composition containing a specific angiotensin II receptor antagonist, such as CS-866 ((5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazol-5-carboxylate) (U.S. Pat. No. 5,616,599), and a diuretic remain unknown.
- Considering that prevention and/or treatment of hypertension are important, the present inventors investigated combinations of various drugs and found that a pharmaceutical composition containing a specific angiotensin II receptor antagonist, such as CS-866, and one or more diuretics exerts excellent anti-hypertensive effects and hence may be useful as a preventative and/or therapeutic agent for hypertension.
- The present invention provides a pharmaceutical composition containing a specific angiotensin II receptor antagonist and one or more diuretics as the active ingredients (particularly pharmaceutical compositions for preventing or treating hypertension), the use of a specific angiotensin II receptor antagonist and one or more diuretics for manufacturing the pharmaceutical compositions (particularly pharmaceutical compositions for preventing or treating hypertension), a method for preventing or treating (particularly treating) diseases (particularly hypertension) by the administration of a specific angiotensin II receptor antagonist and one or more diuretics to warm-blooded animals (particularly humans) at effective doses, and a pharmaceutical composition for administering simultaneously or sequentially a specific angiotensin II receptor antagonist and one or more diuretics for preventing or treating hypertension.
- The active ingredients of the pharmaceutical composition of this invention include an angiotensin II receptor antagonist selected from the group consisting of a compound having the following formula (I), pharmacologically acceptable salts thereof, pharmacologically acceptable esters thereof and pharmacologically acceptable salts of said esters; and one or more diuretics.
- The compound of formula (I), a salt thereof and the like are known compounds, for example, described in the specification of Japanese Patent Application Kokai No. Hei 5-78328 etc. and the chemical name of the compound of formula (I) is 4(1-hydroxy-1-methylethyl)-2-propyl-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazol-5-carboxylic acid.
- The “pharmacologically acceptable salt” of the compound of formula (I), which is an active ingredient of this invention, includes an alkali metal salt such as sodium salt, potassium salt or lithium salt; an alkaline earth metal salt such as calcium salt or magnesium salt; a metal salt such as aluminum salt, iron salt, zinc salt, copper salt, nickel salt or cobalt salt; or an amine salt such as ammonium salt, t-octylamine salt, dibenzylamine salt, morpholine salt, glucosamine salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine salt, N-benzylphenethylamine salt, piperazine salt, tetramethylammonium salt or tris(hydroxymethyl)aminomethane salt. An alkali metal salt is preferable and the sodium salt is particularly preferable.
- The “pharmacologically acceptable ester” of the compound of formula (I), which is an active ingredient of this invention, is a compound esterified at the carboxyl moiety of the compound of formula (I). A group forming said ester is a group which can be cleaved by a biological process such as hydrolysis in vivo. Such groups include, for example, a (C1-C4)alkoxy-(C1-C4)alkyl group such as methoxymethyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, 1-(isopropoxy)ethyl, 2-methoxyethyl, 2-ethoxyethyl, 1,1-dimethyl-1-methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl or t-butoxymethyl; a (C1-C4)alkoxylated (C1-C4)alkoxy-(C1-C4)alkyl group such as 2-methoxyethoxymethyl; a (C6-C10)aryloxy-(C1-C4)alkyl group such as phenoxymethyl; a halogenated (C1-C4)alkoxy-(C1-C4)alkyl group such as 2,2,2-trichloroethoxymethyl or bis(2-chloroethoxy)methyl; a (C1-C4)alkoxycarbonyl-(C1-C4)alkyl group such as methoxycarbonylmethyl; a cyano-(C1-C4)alkyl group such as cyanomethyl or 2-cyanoethyl; a (C1-C4)alkylthiomethyl group such as methylthiomethyl or ethylthiomethyl; a (C6-C10)arylthiomethyl such as phenylthiomethyl or naphthylthiomethyl; a (C1-C4)alkylsulfonyl-(C1-C4) lower alkyl group, which may be optionally substituted with a halogen atom(s), such as 2-methanesulfonylethyl or 2-trifluoromethanesulfonylethyl; a (C6-C10)arylsulfonyl-(C1-C4)alkyl group such as 2-benzenesulfonylethyl or 2-toluenesulfonylethyl; an aliphatic (C1-C7)acyloxy-(C1-C4)alkyl group such as formyloxymethyl, acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl, valeryloxymethyl, isovaleryloxymethyl, hexanoyloxymethyl, 1-formyloxyethyl, 1-acetoxyethyl, 1-propionyloxyethyl, 1-butyryloxyethyl, 1-pivaloyloxyethyl, 1-valeryloxyethyl, 1-isovaleryloxyethyl, 1-hexanoyloxyethyl, 2-formyloxyethyl, 2-acetoxyethyl, 2-propionyloxyethyl, 2-butyryloxyethyl, 2-pivaloyloxyethyl, 2-valeryloxyethyl, 2-isovaleryloxyethyl, 2-hexanoyloxyethyl, 1-folrmyloxypropyl, 1-acetoxypropyl, 1-propionyloxypropyl, 1-butyryloxypropyl, 1-pivaloyloxypropyl, 1-valeryloxypropyl, 1-isovaleryloxypropyl, 1-hexanoyloxypropyl, 1-acetoxybutyl, 1-propionyloxybutyl, 1-butyryloxybutyl, 1-pivaloyloxybutyl, 1-acetoxypentyl, 1-propionyloxypentyl, 1-butyryloxypentyl, 1-pivaloyloxypentyl, or 1-pivaloyloxyhexyl; a (C5-C6)cycloalkylcarbonyloxy-(C1-C4)alkyl group such as cyclopentylcarbonyloxymethyl, cyclohexylcarbonyloxymethyl, 1-cyclopentylcarbonyloxyethyl, 1-cyclohexylcarbonyloxyethyl, 1-cyclopentylcarbonyloxypropyl, 1-cyclohexylcarbonyloxypropyl, 1-cyclopentylcarbonyloxybutyl or 1-cyclohexylcarbonyloxybutyl; a (C6C10)arylcarbonyloxy-(C1-C4)alkyl group such as benzoyloxymethyl; a (C1-C6)alkoxycarbonyloxy-(C1-C4)alkyl group such as methoxycarbonyloxymethyl, 1-(methoxycarbonyloxy)ethyl, 1-(methoxycarbonyloxy)propyl, 1-(methoxycarbonyloxy)butyl, 1-(methoxycarbonyloxy)pentyl, 1-(methoxycarbonyloxy)hexyl, ethoxycarbonyloxymethyl, 1-(ethoxycarbonyloxy)ethyl, 1-(ethoxycarbonyloxy)propyl, 1-ethoxycarbonyloxy)butyl, 1-(ethoxycarbonyloxy)pentyl, 1-(ethoxycarbonyloxy)hexyl, propoxycarbonyloxymethyl, 1-(propoxycarbonyloxy)ethyl, 1-(propoxycarbonyloxy)propyl, 1-(propoxycarbonyloxy)butyl, isopropoxycarbonyloxymethyl, 1-(isopropoxycarbonyloxy)ethyl, 1-(isopropoxycarbonyloxy)butyl, butoxycarbonyloxymethyl, 1 (butoxycarbonyloxy)ethyl, 1-(butoxycarbonyloxy)propyl, 1-(butoxycarbonyloxy)butyl, isobutoxycarbonyloxymethyl, 1-(isobutoxycarbonyloxy)ethyl, 1-(isobutoxycarbonyloxy)propyl, 1-(isobutoxycarbonyloxy)butyl, t-butoxycarbonyloxymethyl, 1-(t-butoxycarbonyloxy)ethyl, pentyloxycarbonyloxymethyl, 1-(pentyloxycarbonyloxy)ethyl, 1-(pentyloxycarbonyloxy)propyl, hexyloxycarbonyloxymethyl, 1-(hexyloxycarbonyloxy)ethyl or 1-(hexyloxycarbonyloxy)propyl; a (C5-C6)cycloalkyloxycarbonyloxy-(C1-C4)alkyl group such as cyclopentyloxycarbonyloxymethyl, 1-(cyclopentyloxycarbonyloxy)ethyl, 1-(cyclopentyloxycarbonyloxy)propyl, 1-(cyclopentyloxycarbonyloxy)butyl, cyclohexyloxycarbonyloxymethyl, 1-(cyclohexyloxycarbonyloxy)ethyl, 1-(cyclohexyloxycarbonyloxy)propyl, or 1-(cyclohexyloxycarbonyloxy)butyl; a [5-(C1-C4)alkyl-2-oxo-1,3-dioxoienyl)methyl group such as (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl, (5-ethyl-2-oxo-1,3-dioxolen-4-yl)methyl, (5-propyl-2-oxo-1,3-dioxolen-4-yl)methyl, (5-isopropyl-2-oxo-1,3-dioxolen-4-yl)methyl, (5-butyl-2-oxo-1,3-dioxolen-4-yl)methyl; [5-(phenyl, which may be optionally substituted with a (C1-C4)alkyl, (C1-C4)alkoxy group(s) or halogen atom(s))-2-oxo-1,3-dioxolen-4-yl]methyl group such as (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl, [5-(4-methylphenyl)-2-oxo-1,3-dioxolen-4-yl]methyl, [5-(4-methoxyphenyl)-2-oxo-1,3-dioxolen-4-yl)methyl, [5-(4-fluorophenyl)-2-oxo-1,3-dioxolen-4-yl)methyl, [5-(4-chlorophenyl)-2-oxo-1,3-dioxolen-4-yl]methyl; or a phthalidyl group, which may be optionally substituted with a (C1-C4)alkyl or (C1-C4)alkoxy group(s), such as phthalidyl, dimethylphthalidyl or dimethoxyphthalidyl. Preferred ester groups are a pivaloyloxymethyl group, phthalidyl group or (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group and the more preferred ester group is a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group.
- The “pharmacologically acceptable salt of the pharmacologically acceptable ester” of the compound of formula (I), which is an active ingredient of this invention, includes a pharmacologically acceptable salt of the “pharmacologically acceptable ester” described above, for example, a hydrohalogenic acid salt such as hydrofluoride, hydrochloride, hydrobromide or hydroiodide; nitrate; perchlorate; sulfate; phosphate; a C1-C4 alkanesulfonic acid salt, which may be optionally substituted with a halogen atom(s) such as methanesulfonate, trifiuoromethanesulfonate or ethanesulfonate; a C6-C10 arylsulfonic acid salt, which may be optionally substituted with a C1-C4 alkyl group(s), such as benrenesulfonate or p-toluenesulfonate; a C1-C6 aliphatic acid salt such as acetate, malate, fumarate, succinate, citrate, tartrate, oxalate or maleate; or an amino acid salt such as a glycine salt, lysine salt, alginine salt, ornitine salt, glutamic acid salt or aspartic acid salt. Preferred salts are hydrochloride, nitrate, sulfate or phosphate and the particularly preferred salt is hydrochloride.
- The angiotensin II receptor antagonist, which is an active ingredient of this invention, is preferably the compound of formula (I) or a pharmacologically acceptable ester thereof, more preferably a pharmacologically acceptable ester of the compound of formula (I), and still more preferably the pivaloyloxymethyl, phthalidyl or (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of compound of formula (I). The most preferred compound is (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazol-5-carboxylate (CS-866).
- The compound of formula (I), which is an active ingredient of this invention, may absorb water or an organic solvent to form a hydrate or a solvate and the present invention encompasses such hydrates and solvates.
- The diuretics, which are another active ingredient of this invention, are known compounds and, for example, include sulfonamide compounds such as acetazolamide, methazolamide, ethoxzolamide, clofenamide, dichlorphenamide, disulfamide, mefruside, chlorthalidone, quinethazone, furosemide, clopamide, tripamide, indapamide, chlorexolone, metolazone, xipamide, bumetanide, piretanide and X-54; thiazide compounds such as hydrochlorothiazide, methylclothiazide, benzylhydrochlorothiazide, trichloromethiazide, cyclopenthiazide, polythiazide, ethiazide, cyclothiazide, bendroflumethiazide, and hydroflumethiazide; phenoxyacetic acid compounds such as ethacrynic acid, tienilic acid, indacrinone and quincarbate; triamterene; amiloride; spironolactone; potassium canrenoate; torasemide; MK447; and traxanox sodium which have been disclosed in U.S. Pat. No. 2,554,816, U.S. Pat. No. 2,980,679, U.S. Pat. No. 2,783,241, GB 795,174, J. Chem. Soc., 1125 (1928), U.S. Pat. No. 2,835,702, GB 851,287, U.S. Pat. No. 3,356,692,U.S. Pat. No. 3,055,904, U.S. Pat. No. 2,976,289, U.S. Pat. No. 3,058,882, Helv. Chim. Acta, 45, 2316 (1962), Pharmacometrics, 21, 607 (1982), U.S. Pat. No. 3,183,243, U.S. Pat. No. 3,360,518, U-SP 3,567,777, U.S. Pat. No. 3,634,583, U.S. Pat. No. 3,025,292, J. Am. Chem. Soc., 82, 1132 (1960), U.S. Pat. No. 3,108,097, Experientia, 16, 113 (1960), J. Org. Chem., 2, 2814 (1961), U.S. Pat. No. 3,009,911, U.S. Pat. No. 3,265,573, U.S. Pat. No. 3,254,076, U.S. Pat. No. 3,255,241, U.S. Pat. No. 3,758,506, BE 639,386 and U.S. Pat. No. 3,163,645. The preferred diuretic is a thiazide compound and the more preferred one is hydrochlorothiazide.
-
- The compound name of hydrochlorothiazide is 6-chloro-3,4-dihydro-2H-1,2,4,-benzothiadiazin-7-sulfonamide 1,1-dioxide. The hydrochlorothiazide of this invention includes pharmacologically acceptable salts thereof, for example, a hydrohalogenic acid salt such as hydrofluoride, hydrochloride, hydrobromide or hydroiodide; nitrate; perchlorate; sulfate; phosphate; a C1-C4 alkanesulfonic acid salt, which may be optionally substituted with a halogen atom(s) such as methanesulfonate, trifiuoromethanesulfonate or ethanesulfonate; a C6-C10 arylsulfonic acid salt, which may be optionally substituted with a C1-C4 alkyl group(s), such as benzenesulfonate or p-toluenesulfonate; a C1-C6 aliphatic acid salt such as acetate, malate, fumarate, succinate, citrate, tartrate, oxalate or maleate; or an amino acid salt such as the glycine salt, lysine salt, alginine salt, ornitine salt, glutamic acid salt or aspartic acid salt. The preferred salts are the hydrochloride, nitrate, sulfate or phosphate and the particularly preferred salt is hydrochloride.
- When the diuretic described hereinbefore has an asymmetric carbon(s), the present invention encompasses individual optical isomers and mixtures thereof. The present invention also encompasses hydrates of the compound described hereinbefore.
- The diuretic of this invention is selected from one or more compounds described hereinbefore and preferably one diuretic agent is selected, which is used in combination with an angiotensin II receptor antagonist such as CS-866.
- Preferred pharmaceutical compositions of this invention are:
-
- (1) a pharmaceutical composition wherein the diuretic is a sulfonamide compound, a phenoxyacetic acid compound or a thiazide compound;
- (2) a pharmaceutical composition wherein the diuretic is a thiazide compound;
- (3) a pharmaceutical composition wherein the diuretic is selected from the group consisting of hydrochlorothiazide, methylclothiazide, benzylhydrochlorothiazide, trichloromethiazide, cyclopenthiazide, polythiazide, ethiazide, cyclothiazide, bendroflumethiazide and hydroflumethiazide; or
- (4) a pharmaceutical composition wherein the diuretic is hydrochlorothiazide.
- Since the present invention, i.e., pharmaceutical compositions containing a specific angiotensin II receptor antagonist, such as CS-866, and one or more diuretics, exerts excellent antihypertensive actions and has low toxicities, the pharmaceutical compositions are useful as remedies, i.e., preferably preventative or therapeutic agents for hypertension, heart diseases (angina pectoris, cardiac failure, cardiac hypertrophy), vascular disorders (arteriosclerosis, post-PTCA restenosis, peripheral vascular disorders), renal diseases (diabetic nephropathy, glomerular nephritis, nephrosclerosis); more preferably preventative and/or therapeutic agents (particularly therapeutic agents) for hypertension or heart diseases; and most preferably preventative or therapeutic agents (particularly therapeutic agents) for hypertension]. The remedies described above are preferably applied to warm-blooded animals, especially to humans.
- According to the present invention, the specific angiotensin II receptor antagonist such as CS-866 and diuretics exert better therapeutic efficacy by combined administration rather than when used separately. In addition, these agents exert excellent efficacy when administered to the same warm-blooded animal at different times. It is speculated that when the 2 groups of compounds employed in the present invention are absorbed in warm-blooded animals, they switch on the signals at their respective receptors to cause their pharmacological actions. Hence, even when their plasma concentrations decrease below the threshold plasma levels to cause each drug's effects the switches located at their receptors have already been turned on and so the preventative or therapeutic effects on hypertension caused by the first drug are seen. The effects of the compound that is administered later are superimposed on those of the former drug. Thus the actions of these 2 agents are additive and excellent effects can be observed. Since it is clinically convenient if these 2 agents are administered at the same time, the specific angiotensin II receptor antagonist, such as CS-866, and the diuretics can be administered at the same time as a single pharmaceutical composition. In the case that these agents cannot adequately be mixed physically from formulation techniques, each compound may be separately administered at the same time. Furthermore, as described above, since these 2 groups of agents do not necessarily have to be administered at the same time to get excellent therapeutic efficacy, the compounds may be administered at appropriate intervals. The maximum acceptable time interval to administer these 2 groups of compounds to obtain excellent treatment or preventative efficacy can be confirmed clinically or preclinically.
- The administration route of specific angiotensin II receptor antagonists, such as CS-866, and diuretics is generally oral. Thus these 2 groups of compounds can be prepared as separate single formulations of each or as a single formulation by physically mixing these 2 groups of compounds. Administration formulations are, for instance, powder, granules, tablets, capsules, etc. The free compounds or pharmacologically acceptable salts or esters thereof are mixed with constituents, diluents, etc., and prepared according to conventional preparation techniques as described below.
- Namely, preparations as described above are manufactured by conventionally known methods using additive agents, i.e., carriers such as diluents (for instance, organic diluents including sugar derivatives such as lactose, sucrose, glucose, mannitol, sorbitol; starch derivatives such as cornstarch, potatostarch, α-starch, and dextrin; cellulose derivatives such as crystalline cellulose; gum arabic; dextran; pullulan; and inorganic diluents including silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, calcium silicate, magnesium aluminometasilicate; phosphate derivatives such as calcium hydrogenphosphate; carbonates such as calcium carbonate; and sulfate derivatives such as calcium sulfate), lubricants (for instance, metallic salts of stearic acid such as stearic acid, calcium stearate, magnesium stearate; talc; waxes such as beeswax, spermaceti; boric acid; adipic acid; sulfates such as sodium sulfate; glycol; fumaric acid; sodium benzoate; DL-leucine; laurylsulphates such as sodium lauryl sulfate, magnesium lauryl sulfate; silicates such as anhydrous silicic acid, silicic acid hydrates; and starch derivatives described above can be listed), binders (for instance, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, macrogol, and similar diluents described above), disintegrators (for instance, cellulose derivatives such as low-substituted hydroxypropylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, and internally bridged-sodium carboxymethylcellulose; chemically modified starch/cellulose derivatives such as carboxymethylstarch, sodium carboxymethylstarch, bridged polyvinylpyrrolidone; and starch derivatives described above), demulsifiers (for instance, colloidal clay such as bentonite and veegum; metal hydrates such as magnesium hydroxide, aluminum hydroxide; anionic surfactants such as sodium lauryl sulfate, calcium stearate; cationic surfactants such as benzalkoniumchloride; and non-ionic surfactants such as polyoxyethylenealkyl ether, and polyoxyethylene sorbitan fatty acid ester, and sucrose esters fatty acids), stabilizers (for instance, parahydroxybenzoates such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzylalcohol, phenylethylalcohol; benzalkonium chloride; phenols such as phenol and cresol; thimerosal; dehydroacetic acid; and sorbic acid), flavors (for instance, sweeteners, acidifiers, and conventionally used flavors), etc.
- The dose and rate of administration of the specific angiotensin II receptor antagonist, such as CS-866, and diuretics depend upon various factors such as the drugs' activities, symptoms, age, and body weight of the patients. However, generally speaking, the adult dosage (mg dose/time) of the specific angiotensin II receptor antagonist and diuretics is 0.5 to 1,000 mg (preferably 1 to 100 mg) and about 0.05 to 1,500 mg (preferably 5 to 300 mg), respectively. Compounds are administered once or several times per day, depending upon the symptoms of the patients.
- Dosing ratios of the drugs in the 2 categories may also be varied. However, generally speaking, the rates of the specific angiotensin II receptor antagonist, such as CS-866, and diuretics are 1:200 to 200:1 as their weight ratios.
- In the present invention, the specific angiotensin II receptor antagonist, such as CS-866, and diuretics are simultaneously administered, or separately or sequentially administered at the doses described above.
- The present invention is described in more detail by way of the following Examples. However, the present invention is not limited to these examples.
- Hypotensive Effects Elicited by Co-Administration of CS-866 and Hydrochlorothiazide
- Twenty-eight male spontaneously hypertensive rats aged 20 weeks (SHRs, SPF grade, purchased from Hoshino Laboratory Animals) were used. A transmitter of a telemeter (TA11PA-C40, DATA SCIENCES Inc.) was implanted in each SHR for recording blood pressure. After recovery from the surgical operations, blood pressure was monitored in the rats from the age of 24 weeks. The rats were orally given 0.5% carboxymethylceflulose solution (CMC, 2 ml/kg) for 7 successive days (once daily) by gavage. They were divided into 4 groups (7 SHRs per group) so as to give equally averaged blood pressure levels in the groups based on the blood pressure recorded on the 5th and 6th days after the CMC solution was initiated. The rats were orally treated with 0.5% CMC solution (2 ml/kg, control group) or test substance suspended in 0.5% CMC solution (2 ml/kg) for 14 successive days (once daily). Blood pressure was monitored 1 day prior to the drug administration and on the 7th and 14th days after the drug was initiated. The group composition, test substances, doses and blood pressure (the 24 hour mean blood pressure A standard error on the respective monitoring days) are summarized in Tables 1 and 2.
- The test substances were hydrochlorothiazide (HCTZ), CS-866, and HCTZ and CS-866. HCTZ was prepared so as to be 10 mg/2 ml of final concentration with 0.5% CMC solution. CS-866 was suspended in 0.5% CMC solution so as to be at a final concentration of 1 mg/2 ml. CS-866 and HCTZ solution was prepared so as to be at a final concentration of [10 mg (HCTZ)+1 mg (CS-866)]/2 ml with 0.5% CMC solution.
TABLE 1 Group composition and administration of the test substance Group 1 Control 0.5% CMC solution Group 2 HCTZ HCTZ (10 mg/kg) Group 3 CS-866 CS-866 (1 mg/kg) Group 4 HCTZ and CS-866 HCTZ (10 mg/kg) + CS-866 (1 mg/kg) -
TABLE 2 Blood pressure levels Group 1 Group 2 Group 3 Group 4 1 day before administration 167 ± 6 165 ± 6 167 ± 6 165 ± 4 7th day after administration 163 ± 6 152 ± 6 147 ± 4 132 ± 4 14th day after administration 166 ± 7 156 ± 6 148 ± 4 134 ± 4 - As summarized in Table 2, coadministration of CS-866 and HCTZ (Group 4) showed a more excellent hypotensive action than those elicited by each of the agents CS-866 and HCTZ alone (Group 2 or 3).
-
Tablets CS-866 10.0 mg Hydrochlorothiazide 12.5 mg Lactose 275.5 mg Cornstarch 50.0 mg Magnesium stearate 2.0 mg Total 350 mg - The powders described above are mixed well, and tableted with a tableting machine to prepare a tablet containing 350 mg. The tablets can be sugar coated if desired.
Claims (33)
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with a pharmaceutically effective amount of each of (i) an angiotensin II receptor antagonist selected from the group consisting of a compound having the following formula (I):
, a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of said ester thereof, and (ii) a diuretic which is at least one thiazide compound.
2. The pharmaceutical composition according to claim 1 , wherein the angiotensin II receptor antagonist is the compound of the formula (I) or a pharmacologically acceptable ester thereof.
3. The pharmaceutical composition according to claim 1 , wherein the angiotensin II receptor antagonist is a pharmacologically acceptable ester of the compound of the formula (I).
4. The pharmaceutical composition according to claim 1 , wherein the angiotensin II receptor antagonist is the pivaloyloxymethyl ester, phthalidyl ester, or (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of the compound of the formula (I).
5. The pharmaceutical composition according to claim 1 , wherein the angiotensin II receptor antagonist is the (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of the compound of the formula (I).
6. The pharmaceutical composition according to claim 1 , wherein the diuretic is selected from the group consisting of hydrochlorothiazide, methylclothiazide, benzylhydrochlorothiazide, trichlormethiazide, cyclopenthiazide, polythiazide, ethiazide, cyclothiazide, bendroflumethiazide and hydroflumethiazide.
7. The pharmaceutical composition according to claim 1 , wherein the diuretic is hydrochlorothiazide.
8. The pharmaceutical composition according to claim 1 , wherein the angiotensin II receptor antagonist is the pivaloyloxymethyl ester, phthalidyl ester, or (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of the compound of the formula (I) and the diuretic is selected from the group consisting of hydrochlorothiazide, methyldlothiazide, benzylhydrochlorothiazide, trichlormethiazide, cyclopenthiazide, polythiazide, ethiazide, cyclothiazide, bendroflumethiazide and hydroflumethiazide.
9. The pharmaceutical composition according to claim 1 , wherein the angiotensin II receptor antagonist is the (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of the compound of the formula (I) and the diuretic is hydrochlorothiazide.
10. The pharmaceutical composition according to claim 1 , wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1.
11. The pharmaceutical composition according to claim 8 , wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1.
12. The pharmaceutical composition according to claim 9 , wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1.
13. The pharmaceutical composition according to claim 1 , wherein the composition has a hypotensive action.
14. The pharmaceutical composition according to claim 1 , wherein the angiotensin II receptor antagonist is in a first dosage form and the diuretic is in a second dosage form.
15. The pharmaceutical composition according to claim 1 , wherein the angiotensin II receptor antagonist and the diuretic are in a single unit dosage.
16. A method for treating hypertension by administering to a warm-blooded animal a pharmaceutically effective amount of each of (i) an angiotensin II receptor antagonist selected from the group consisting of a compound having the following formula (I):
, a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of said ester thereof, and (ii) at least one diuretic selected from the group consisting of methylclothiazide, benzylhydrochlorothiazide, trichlormethiazide, cyclopenthiazide, polythiazide, ethiazide, cyclothiazide, bendroflumethiazide and hydroflumethiazide.
17. The method according to claim 16 , wherein the warm-blooded animal is a human.
18. The method according to claim 17 , wherein the angiotensin II receptor antagonist is the compound of the formula (I) or a pharmacologically acceptable ester thereof.
19. The method according to claim 17 , wherein the angiotensin II receptor antagonist is a pharmacologically acceptable ester of the compound of the formula (I).
20. The method according to claim 17 , wherein the angiotensin II receptor antagonist is the pivaloyloxymethyl ester, phthalidyl ester or (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of the compound of the formula (I).
21. The method according to claim 17 , wherein the angiotensin II receptor antagonist is the (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of the compound of the formula (I).
22. The method according to claim 20 , wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1.
23. The method according to claim 21 , wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1.
24. The method according to claim 17 , wherein the compound of the formula (I) is administered at least once a day in an amount of 0.5 to 1,000 mg and the diuretic is administered at least once a day in an amount of 0.05 to 1,500 mg.
25. The method according to claim 17 , wherein the compound of the formula (I) is administered at least once a day in an amount of 1 to 100 mg and the diuretic is administered at least once a day in an amount of 5 to 300 mg.
26. The method according to claim 17 , wherein the angiotensin II receptor antagonist is in a first dosage form and the diuretic is in a second dosage form.
27. The method according to claim 17 , wherein the angiotensin II receptor antagonist and the diuretic are in a single dosage form.
28. A method for preventing or treating a disease or condition selected from the group consisting of angina pectoris, cardiac failure, cardiac hypertrophy, arteriosclerosis, post-PTCA restenosis, a peripheral vascular disorder, diabetic nephropathy, glomerular nephritis and nephrosclerosis, comprising administering to a warm-blooded animal a pharmaceutically effective amount of each of (i) an angiotensin II receptor antagonist selected from the group consisting of a compound having the following formula (I):
, a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of said ester thereof, and (ii) at least one diuretic.
29. The method according to claim 28 , wherein the method is for treating a human.
30. The method according to claim 29 , wherein the angiotensin II receptor antagonist is the (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of the compound of the formula (I) and the diuretic is hydrochlorothiazide.
31. The method according to claim 30 , wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1.
32. The method according to claim 28 , wherein the angiotensin II receptor antagonist is in a first dosage form and the diuretic is in a second dosage form.
33. The method according to claim 29 , wherein the angiotensin H receptor antagonist and the diuretic are in a single unit dosage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/020,624 US20050113367A1 (en) | 2000-11-21 | 2004-12-23 | Pharmaceutical composition |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-354327 | 2000-11-21 | ||
JP2000354327 | 2000-11-21 | ||
JP2001-164009 | 2001-05-31 | ||
JP2001164009 | 2001-05-31 | ||
PCT/JP2001/010095 WO2002041890A1 (en) | 2000-11-21 | 2001-11-19 | Medicinal compositions |
US10/442,874 US6878703B2 (en) | 2000-11-21 | 2003-05-20 | Pharmaceutical composition |
US11/020,624 US20050113367A1 (en) | 2000-11-21 | 2004-12-23 | Pharmaceutical composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/442,874 Continuation US6878703B2 (en) | 2000-11-21 | 2003-05-20 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050113367A1 true US20050113367A1 (en) | 2005-05-26 |
Family
ID=26604360
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/442,874 Expired - Fee Related US6878703B2 (en) | 2000-11-21 | 2003-05-20 | Pharmaceutical composition |
US11/020,624 Abandoned US20050113367A1 (en) | 2000-11-21 | 2004-12-23 | Pharmaceutical composition |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/442,874 Expired - Fee Related US6878703B2 (en) | 2000-11-21 | 2003-05-20 | Pharmaceutical composition |
Country Status (24)
Country | Link |
---|---|
US (2) | US6878703B2 (en) |
EP (2) | EP1336407B1 (en) |
KR (1) | KR100656716B1 (en) |
CN (1) | CN1265788C (en) |
AT (1) | ATE324890T1 (en) |
AU (2) | AU2002214324B2 (en) |
BR (1) | BR0115516A (en) |
CA (1) | CA2429260A1 (en) |
CY (1) | CY1106134T1 (en) |
CZ (1) | CZ20031367A3 (en) |
DE (1) | DE60119368T2 (en) |
DK (1) | DK1336407T3 (en) |
ES (1) | ES2262689T3 (en) |
HK (1) | HK1054692A1 (en) |
HU (1) | HUP0400553A3 (en) |
IL (2) | IL155965A0 (en) |
MX (1) | MXPA03004463A (en) |
NO (1) | NO332938B1 (en) |
NZ (1) | NZ525913A (en) |
PL (1) | PL207252B1 (en) |
PT (1) | PT1336407E (en) |
SK (1) | SK5992003A3 (en) |
TW (1) | TWI262076B (en) |
WO (1) | WO2002041890A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060074117A1 (en) * | 2004-09-02 | 2006-04-06 | Lilach Hedvati | Purification of olmesartan medoxomil |
US20070054948A1 (en) * | 2004-09-02 | 2007-03-08 | Lilach Hedvati | Purification of olmesartan medoxomil |
US20070237235A1 (en) * | 2006-03-28 | 2007-10-11 | Sony Corporation | Method of reducing computations in transform and scaling processes in a digital video encoder using a threshold-based approach |
WO2008054121A1 (en) * | 2006-10-30 | 2008-05-08 | Hanall Pharmaceutical Company. Ltd | Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101194453B1 (en) * | 2003-01-31 | 2012-10-24 | 다이이찌 산쿄 가부시키가이샤 | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
AU2004270162B2 (en) | 2003-08-28 | 2010-05-13 | Nicox S.A. | Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use |
US7528258B2 (en) * | 2004-09-02 | 2009-05-05 | Teva Pharmaceutical Industries Ltd | Preparation of olmesartan medoxomil |
WO2006091716A2 (en) | 2005-02-24 | 2006-08-31 | Nitromed, Inc. | Nitric oxide enhancing diuretic compounds, compositions and methods of use |
KR101318032B1 (en) * | 2005-05-20 | 2013-10-14 | 다이이찌 산쿄 가부시키가이샤 | Film coated preparation |
JP4979577B2 (en) * | 2005-05-20 | 2012-07-18 | 第一三共株式会社 | Dextrose-containing film coating formulation |
WO2007047838A2 (en) * | 2005-10-20 | 2007-04-26 | Dr. Reddy's Laboratories Ltd. | Process for preparing olmesartan medoxomil |
ATE526963T1 (en) * | 2006-05-04 | 2011-10-15 | Lek Pharmaceuticals | PHARMACEUTICAL COMPOSITION CONTAINING OLMESARTAN-MEDOXOMIL |
EP2253318B1 (en) | 2008-03-13 | 2014-08-06 | Daiichi Sankyo Company, Limited | Improvement of dissolvability of preparation containing olmesartan medoxomil |
US20100008956A1 (en) * | 2008-07-08 | 2010-01-14 | Jie Du | Composition and combinations of carboxylic acid losartan in dosage forms |
DE102008059206A1 (en) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic |
WO2010075347A2 (en) | 2008-12-23 | 2010-07-01 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone |
IT1400311B1 (en) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | ASSOCIATION OF INHIBITORS OF XANTHIN OXIDASE AND ANTAGONISTS OF THE Angiotensin II RECEPTOR AND THEIR USE. |
US11081240B2 (en) | 2018-06-14 | 2021-08-03 | Astrazeneca Uk Limited | Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2783241A (en) | 1957-02-26 | S-acylimino-x-substituted-az-i | ||
US3009911A (en) | 1961-11-21 | Derivatives of j | ||
US3254076A (en) | 1966-05-31 | Sulfamyl hydro | ||
US3025292A (en) | 1962-03-13 | Reduction of i | ||
US2976289A (en) | 1961-03-21 | X-tetrahydro - | ||
US3108097A (en) | 1963-10-22 | Ehnojs | ||
US2554816A (en) | 1950-04-04 | 1951-05-29 | American Cyanamid Co | Heterocyclic sulfonamides and methods of preparation thereof |
GB795174A (en) | 1954-10-13 | 1958-05-21 | Upjohn Co | Heterocyclic sulphonamides |
US2835702A (en) | 1956-05-02 | 1958-05-20 | Merck & Co Inc | Benzene 1, 3 disulfonamides possessing diuretic properties |
US2980679A (en) | 1957-04-04 | 1961-04-18 | Omikron Gagliardi Societa Di F | Process for preparing heterocyclic sulfonamides |
US3055904A (en) | 1957-11-04 | 1962-09-25 | Geigy Chem Corp | New isoindoline derivatives |
GB851287A (en) | 1958-07-10 | 1960-10-12 | British Drug Houses Ltd | 5-chlorotoluene-2:4-disulphonamide and alkali metal salts thereof |
US3058882A (en) | 1959-12-28 | 1962-10-16 | Hoechst Ag | N'-substituted-3-carboxy-6-halo-sulfanilamide and derivatives thereof |
US3255241A (en) | 1961-01-19 | 1966-06-07 | Merck & Co Inc | (2-alkylidene acyl)phenoxy-and (2-alkylidene acyl)phenylmercaptocarboxylic acids |
GB979994A (en) | 1961-07-28 | 1965-01-06 | May & Baker Ltd | Isoindolinone derivatives |
US3265573A (en) | 1962-07-27 | 1966-08-09 | Squibb & Sons Inc | Benzothiadiazinesulfonamide-1, 1-dioxide composition |
BE639386A (en) | 1962-10-30 | |||
DE1278443C2 (en) | 1963-11-30 | 1975-07-24 | Bayer Ag, 5090 Leverkusen | PROCESS FOR THE PREPARATION OF 2,4-DISULFONAMIDE-1-CHLOROBENZENE |
US3163645A (en) | 1964-09-25 | 1964-12-29 | Ciba Geigy Corp | Derivatives of 3, 4-dihydro-2-h-[1, 2, 4]-benzothiadiazine-1, 1-dioxides |
DE1270544B (en) | 1965-06-19 | 1968-06-20 | Beiersdorf Ag | 4-chloro-5-sulfamylsalicylic acid (2 ', 6'-dimethyl) anilide and its alkali or ammonium salts and processes for their preparation |
US3360518A (en) | 1966-01-03 | 1967-12-26 | Wallace & Tiernan Inc | Tetrahydro-halo-sulfamyl quinazolinones |
US3634583A (en) | 1969-07-24 | 1972-01-11 | Leo Pharm Prod Ltd | Pharmaceutical composition for the treatment of oedematous conditions and hypertension |
BE757001A (en) | 1969-10-10 | 1971-03-16 | Cerpha | HETEROCYCLIC DERIVATIVES OF PHENOXY ACETIC ACIDS AND THEIR PREPARATION |
US5138069A (en) | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
EP0733366B1 (en) * | 1988-01-07 | 1998-04-01 | E.I. Du Pont De Nemours And Company | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics |
CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
CA2016710A1 (en) * | 1989-05-15 | 1990-11-15 | Prasun K. Chakravarty | Substituted benzimidazoles as angiotensin ii antagonists |
US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
CA2061607C (en) * | 1991-02-21 | 1999-01-19 | Hiroaki Yanagisawa | 1-biphenylimidazole derivatives, their preparation and their therapeutic use |
US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
US5310928A (en) | 1991-11-18 | 1994-05-10 | E. I. Du Pont De Nemours And Company | Process for preparing biphenyltetrazole compounds |
US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
-
2001
- 2001-11-19 NZ NZ525913A patent/NZ525913A/en not_active IP Right Cessation
- 2001-11-19 BR BR0115516-4A patent/BR0115516A/en not_active Application Discontinuation
- 2001-11-19 PT PT01982846T patent/PT1336407E/en unknown
- 2001-11-19 CA CA002429260A patent/CA2429260A1/en not_active Abandoned
- 2001-11-19 WO PCT/JP2001/010095 patent/WO2002041890A1/en active IP Right Grant
- 2001-11-19 KR KR1020037006752A patent/KR100656716B1/en active IP Right Review Request
- 2001-11-19 EP EP01982846A patent/EP1336407B1/en not_active Revoked
- 2001-11-19 AU AU2002214324A patent/AU2002214324B2/en not_active Expired
- 2001-11-19 CN CNB018221130A patent/CN1265788C/en not_active Expired - Lifetime
- 2001-11-19 PL PL361093A patent/PL207252B1/en unknown
- 2001-11-19 DE DE60119368T patent/DE60119368T2/en not_active Expired - Lifetime
- 2001-11-19 DK DK01982846T patent/DK1336407T3/en active
- 2001-11-19 MX MXPA03004463A patent/MXPA03004463A/en active IP Right Grant
- 2001-11-19 EP EP05008297A patent/EP1595540A1/en not_active Withdrawn
- 2001-11-19 ES ES01982846T patent/ES2262689T3/en not_active Expired - Lifetime
- 2001-11-19 AT AT01982846T patent/ATE324890T1/en active
- 2001-11-19 AU AU1432402A patent/AU1432402A/en active Pending
- 2001-11-19 CZ CZ20031367A patent/CZ20031367A3/en unknown
- 2001-11-19 SK SK599-2003A patent/SK5992003A3/en not_active Application Discontinuation
- 2001-11-19 IL IL15596501A patent/IL155965A0/en unknown
- 2001-11-19 HU HU0400553A patent/HUP0400553A3/en unknown
- 2001-11-21 TW TW090128798A patent/TWI262076B/en not_active IP Right Cessation
-
2003
- 2003-05-18 IL IL155965A patent/IL155965A/en unknown
- 2003-05-20 NO NO20032261A patent/NO332938B1/en not_active IP Right Cessation
- 2003-05-20 US US10/442,874 patent/US6878703B2/en not_active Expired - Fee Related
- 2003-09-29 HK HK03107005A patent/HK1054692A1/en not_active IP Right Cessation
-
2004
- 2004-12-23 US US11/020,624 patent/US20050113367A1/en not_active Abandoned
-
2006
- 2006-07-31 CY CY20061101069T patent/CY1106134T1/en unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060074117A1 (en) * | 2004-09-02 | 2006-04-06 | Lilach Hedvati | Purification of olmesartan medoxomil |
US20070054948A1 (en) * | 2004-09-02 | 2007-03-08 | Lilach Hedvati | Purification of olmesartan medoxomil |
US20100076200A1 (en) * | 2004-09-02 | 2010-03-25 | Lilach Hedvati | Purification of olmesartan medoxomil |
US20070237235A1 (en) * | 2006-03-28 | 2007-10-11 | Sony Corporation | Method of reducing computations in transform and scaling processes in a digital video encoder using a threshold-based approach |
WO2008054121A1 (en) * | 2006-10-30 | 2008-05-08 | Hanall Pharmaceutical Company. Ltd | Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
US20100143470A1 (en) * | 2006-10-30 | 2010-06-10 | Hanall Pharmaceutical Company, Ltd | Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6878703B2 (en) | Pharmaceutical composition | |
EP1898951B1 (en) | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker | |
JP5456857B2 (en) | Solid preparation | |
HRP20050754A2 (en) | Medicine for prevention of and treatment for arteriosclerosis and hypertension | |
JP4107831B2 (en) | Pharmaceutical composition | |
US20120046327A1 (en) | Method for inhibiting the induction and formation of osteoclasts | |
US20070203211A1 (en) | Drug for preventing or treating angiogenic eye diseases | |
WO2009145358A2 (en) | Medicament for the prophylaxis or treatment of hypertension | |
RU2261708C2 (en) | Pharmaceutical composition | |
US20120302614A1 (en) | Method for improving cerebral circulation or treating a cerebral blood flow disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANKYO COMPANY, LIMITED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SADA, TOSHIO;MIZUNO, MAKOTO;REEL/FRAME:016129/0271 Effective date: 20030618 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |